BioSpace News Archive

Achieves GAAP Profitability with $0.5 Million in Net Income in the First Quarter of 2020

Y-mAbs Therapeutics, Inc. a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported financial results for the first quarter 2020.

Sunesis Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2020.

Company initiates development of CLBS119 for the repair of COVID-19 induced lung damage and expands its proprietary CD34+ cell therapy portfolio

Conatus Pharmaceuticals Inc. convened and adjourned its special meeting of stockholders in order to obtain a quorum and specific stockholder approvals required pursuant to the terms of its merger agreement with Histogen Inc.

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter ended March 31, 2020, and provided operational updates.

New ATLL data presented in the first quarter; Company plans to request a meeting with the FDA on a regulatory pathway for cobomarsen in ATLL during Q2 2020

Fluidigm Corporation announced financial results for the first quarter ended March 31, 2020.

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, announced that the Company will host a conference call and live audio webcast on Thursday, May 14, 2020, at 4:30 p.m. ET, to discuss its corporate and financial results for the first quarter 2020.

Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, reported financial results for the first quarter ended March 31, 2020 and provided an update on recent corporate progress.